Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting

Array BioPharma Inc. (NASDAQ: ARRY) today announced oral presentations on its two MEK inhibitors, selumetinib (AZD6244) and MEK162 at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, which will held June 1-5, 2012 at McCormick Place in Chicago, Illinois. Array invented selumetinib and MEK162 and subsequently licensed them to AstraZeneca and Novartis, respectively.

Three oral presentations at ASCO:


Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC) (Abstract #7503)


Pasi A. Janne, MD, PhD


Monday, June 4, 2012, 5:00 – 5:15 p.m. EDT


Reacquisition of RAI uptake in RAI-refractory metastatic thyroid cancers by pretreatment with the MEK inhibitor selumetinib (Abstract #5509)


Alan L. Ho, MD, PhD


Monday, June 4, 2012, 1:00 – 1:15 p.m. EDT



Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations* (Abstract #8511)


Paolo A. Ascierto, MD


Monday, June 4, 2012, 4:45 – 5:00 p.m. EDT

The abstracts can be accessed through the ASCO website, After June 4, 2012, the oral presentation slides will be available as PDFs on Array's website at

*The abstract submitted for MEK162 does not incorporate data and new findings generated since the time of submission in early 2012. The latest and most up-to-date clinical data will be delivered during the investigator’s presentation at the Annual Meeting itself, at the date and time listed above.

In addition, the following scientific posters on selumetinib and GDC-0068, an Akt inhibitor partnered with Genentech, will be presented at the conference.


ASCO Abstract Title

Presentation Date
and Time (EDT)

3529 Pharmacodynamic biomarker-driven trial of MK-2206, an AKT inhibitor, with AZD6244 (selumetinib), a MEK inhibitor, in patients with advanced colorectal carcinoma (CRC)

Friday, June 1
2 - 6 pm

3020 A phase I, single-institution, open-label, dose escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies

Saturday, June 2
2:15 - 6:15 pm

3021 A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors

Saturday, June 2
2:15 – 6:15 pm

8598 Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma

Sunday, June 3
9 am - 1 pm

3103 A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC)

Monday, June 4
9 am - 1 pm

4100 A phase I/II study of AZD6244 in combination with sorafenib (Nexavar - Bayer/Onyx) in advanced hepatocellular carcinoma

Monday, June 4
9 am - 1 pm

TPS2616 A phase Ib/II study testing the safety and efficacy of combined inhibition of the AKT/PI3K and AR signaling pathways in castration-resistant prostate cancer: GDC-0068 or GDC-0980 with abiraterone acetate versus abiraterone acetate

Monday, June 4
9 am - 1 pm

6582 Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML)

Monday, June 4
2:15 - 6:15 pm

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Array has four core proprietary clinical programs: ARRY-614 for myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded clinical programs including two MEK inhibitors in Phase 2: selumetinib with AstraZeneca and MEK162 with Novartis. For more formation on Array, please go to


Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here